Alzamend Neuro, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Alzamend Neuro, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($4.51M) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | ($9.95M) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | ($14.88M) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | ($12.36M) | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | ($5.05M) | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | ($4.41M) | Jul 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($4.50M) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | ($9.94M) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | ($14.87M) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | ($12.32M) | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | ($4.95M) | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | ($4.42M) | Jul 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $1.41M | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | $6.46M | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | $7.45M | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | $5.20M | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | $1.31M | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | $1.07M | Jul 29, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($6.57M) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | ($8.27M) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | ($8.92M) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | ($6.61M) | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | ($2.71M) | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | ($2.35M) | Jul 29, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $4.60M | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | $631.6K | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | $5.92M | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | $14.52M | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | $2.91M | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | $1.81M | Jul 29, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $634.8K | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | $3.23M | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | $2.87M | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | $1.16M | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | $899.6K | Jul 19, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $3.97M | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | ($2.59M) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | $3.05M | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | $13.35M | Jul 27, 2023 |
| FY2023 | Apr 30, 2021 | $2.01M | Jul 27, 2023 |
| FY2022 | Apr 30, 2020 | $821.7K | Jul 19, 2022 |
| FY2021 | Apr 30, 2019 | $316.9K | Jul 29, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($58.54M) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | ($54.02M) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | ($44.07M) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | ($29.19M) | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | ($16.83M) | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | ($11.79M) | Jul 29, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $3.95M | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | $376.0K | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | $5.14M | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | $14.06M | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | $1.93M | Jul 19, 2022 |
| FY2022 | Apr 30, 2020 | $90.3K | Jul 19, 2022 |
| FY2021 | Apr 30, 2019 | $42.6K | Jul 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (11) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | (132) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | (22) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 27, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | (11) | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | (132) | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | (22) | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 27, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 778,733 | Jul 22, 2025 |
| FY2025 | Apr 30, 2024 | 76,444 | Jul 22, 2025 |
| FY2024 | Apr 30, 2023 | 646,267 | Jul 30, 2024 |
| FY2023 | Apr 30, 2022 | 95.48M | Jul 27, 2023 |
| FY2022 | Apr 30, 2021 | 67.43M | Jul 19, 2022 |
| FY2021 | Apr 30, 2020 | 64.76M | Jul 29, 2021 |